Background: Traditionally, peritoneal surface malignancies (PSM) were considered terminal diseases because of their advanced nature, therefore, systemic chemotherapy was given with palliative intent only. As a result, very poor survival outcomes were observed. But with the introduction of complete Cytoreductive surgery (CRS) and Hyperthermic intraperitoneal chemotherapy (HIPEC), the scenario has changed dramatically. Methodology: An objective electronic database search was performed in Pubmed, NLM Catalog, Google scholar, Bookshelf, and Pubmed Central published in the time period from 2000 till 2020. All the randomized studies were included. In the absence of randomized studies, both prospective and retrospective studies were included. The outcomes of HIPEC were measured in terms of median survival, disease-free survival, overall survival, complications and drug toxicities. Results: CRS and HIPEC are considered the standard of care for PMP and MPM even in the absence of level 1 evidence due to lack of an effective alternative treatment. In colorectal and gastric cancer, several phase-three trials are showing overall survival benefit in selected cases while there is a prophylactic and palliative role of HIPEC in gastric cancer. Three reported phase 3 trials showed positive results in ovarian cancer. In peritoneal sarcomatosis, the role of HIPEC is yet to be proven. Conclusion: The patient selection is the key to the successful outcomes after HIPEC. HIPEC should be performed by the experienced surgeons in specialized centres with a strong critical care and intensive care support to reduce the morbidity and mortality. Ongoing trials and future directions will prove to be an indispensable arm in the oncological armamentarium.

背景：传统上，腹膜表面恶性肿瘤（PSM）由于其晚期性质而被认为是晚期疾病，因此，全身化疗仅具有姑息性目的。结果，观察到非常差的生存结果。但随着完整的细胞减灭术 (CRS) 和腹腔内热疗 (HIPEC) 的引入，情况发生了巨大变化。方法：在 2000 年至 2020 年期间出版的 Pubmed、NLM 目录、谷歌学者、书架和 Pubmed Central 中进行了客观的电子数据库搜索。所有随机研究都包括在内。在没有随机研究的情况下，前瞻性和回顾性研究都包括在内。HIPEC 的结果根据中位生存期、无病生存期、总生存期、并发症和药物毒性来衡量。结果：CRS 和 HIPEC 被认为是 PMP 和 MPM 的护理标准，即使由于缺乏有效的替代治疗而缺乏 1 级证据。在结直肠癌和胃癌中，几项三期试验显示在选定病例中的总体生存获益，同时 HIPEC 在胃癌中具有预防和姑息作用。三项报告的 3 期试验在卵巢癌中显示出阳性结果。在腹膜肉瘤病中，HIPEC 的作用尚未得到证实。结论：患者选择是 HIPEC 后成功结果的关键。HIPEC 应由经验丰富的外科医生在具有强大重症监护和重症监护支持的专业中心进行，以降低发病率和死亡率。正在进行的试验和未来的方向将被证明是肿瘤武器库中不可或缺的武器。